187 related articles for article (PubMed ID: 32042081)
21. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.
Pflug N; Bahlo J; Shanafelt TD; Eichhorst BF; Bergmann MA; Elter T; Bauer K; Malchau G; Rabe KG; Stilgenbauer S; Döhner H; Jäger U; Eckart MJ; Hopfinger G; Busch R; Fink AM; Wendtner CM; Fischer K; Kay NE; Hallek M
Blood; 2014 Jul; 124(1):49-62. PubMed ID: 24797299
[TBL] [Abstract][Full Text] [Related]
22. Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.
Monti P; Lionetti M; De Luca G; Menichini P; Recchia AG; Matis S; Colombo M; Fabris S; Speciale A; Barbieri M; Gentile M; Zupo S; Dono M; Ibatici A; Neri A; Ferrarini M; Fais F; Fronza G; Cutrona G; Morabito F
Sci Rep; 2020 Oct; 10(1):18427. PubMed ID: 33116240
[TBL] [Abstract][Full Text] [Related]
23. Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model.
Molica S; Giannarelli D; Mirabelli R; Levato L; Russo A; Linardi M; Gentile M; Morabito F
Eur J Haematol; 2016 Jan; 96(1):72-7. PubMed ID: 25819739
[TBL] [Abstract][Full Text] [Related]
24. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
Cherng HJ; Jammal N; Paul S; Wang X; Sasaki K; Thompson P; Burger J; Ferrajoli A; Estrov Z; O'Brien S; Keating M; Wierda WG; Jain N
Br J Haematol; 2021 Jul; 194(1):61-68. PubMed ID: 33973230
[TBL] [Abstract][Full Text] [Related]
25. Defining the prognosis of early stage chronic lymphocytic leukaemia patients.
Pepper C; Majid A; Lin TT; Hewamana S; Pratt G; Walewska R; Gesk S; Siebert R; Wagner S; Kennedy B; Miall F; Davis ZA; Tracy I; Gardiner AC; Brennan P; Hills RK; Dyer MJ; Oscier D; Fegan C
Br J Haematol; 2012 Feb; 156(4):499-507. PubMed ID: 22171799
[TBL] [Abstract][Full Text] [Related]
26. Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia.
Göbel M; Eisele L; Möllmann M; Hüttmann A; Johansson P; Scholtysik R; Bergmann M; Busch R; Döhner H; Hallek M; Seiler T; Stilgenbauer S; Klein-Hitpass L; Dührsen U; Dürig J
PLoS One; 2013; 8(8):e72107. PubMed ID: 24009671
[TBL] [Abstract][Full Text] [Related]
27. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
[TBL] [Abstract][Full Text] [Related]
28. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone.
Marasca R; Maffei R; Martinelli S; Fiorcari S; Bulgarelli J; Debbia G; Rossi D; Rossi FM; Rigolin GM; Martinelli S; Gattei V; Del Poeta G; Laurenti L; Forconi F; Montillo M; Gaidano G; Luppi M
Hematol Oncol; 2013 Jun; 31(2):88-95. PubMed ID: 23027683
[TBL] [Abstract][Full Text] [Related]
29. The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index.
Muñoz-Novas C; Poza-Santaella M; González-Gascón Y Marín I; Hernández-Sánchez M; Rodríguez-Vicente AE; Infante MS; Heras C; Foncillas MÁ; Marín K; Hernández-Rivas JM; Hernández JÁ
Biomed Res Int; 2018; 2018():9506979. PubMed ID: 29736400
[TBL] [Abstract][Full Text] [Related]
30. [News in therapeutic management of chronic lymphoid leukemia].
Michallet AS; Salles G; Coiffier B; Michallet M
Bull Cancer; 2005 Mar; 92(3):249-56. PubMed ID: 15820919
[TBL] [Abstract][Full Text] [Related]
31. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome.
Brieghel C; da Cunha-Bang C; Yde CW; Schmidt AY; Kinalis S; Nadeu F; Andersen MA; Jacobsen LO; Andersen MK; Pedersen LB; Delgado J; Baumann T; Mattsson M; Mansouri L; Rosenquist R; Campo E; Nielsen FC; Niemann CU
Clin Cancer Res; 2020 Mar; 26(6):1507-1515. PubMed ID: 31919133
[TBL] [Abstract][Full Text] [Related]
32. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
33. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.
Murphy EJ; Neuberg DS; Rassenti LZ; Hayes G; Redd R; Emson C; Li K; Brown JR; Wierda WG; Turner S; Greaves AW; Zent CS; Byrd JC; McConnel C; Barrientos J; Kay N; Hellerstein MK; Chiorazzi N; Kipps TJ; Rai KR
Leukemia; 2017 Jun; 31(6):1348-1354. PubMed ID: 28115735
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Bühler A; Wendtner CM; Kipps TJ; Rassenti L; Fraser GA; Michallet AS; Hillmen P; Dürig J; Gregory SA; Kalaycio M; Aurran-Schleinitz T; Trentin L; Gribben JG; Chanan-Khan A; Purse B; Zhang J; De Bedout S; Mei J; Hallek M; Stilgenbauer S
Blood Cancer J; 2016 Mar; 6(3):e404. PubMed ID: 26967821
[TBL] [Abstract][Full Text] [Related]
35. A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia.
González-Gascón Y Marín I; Hernández-Sánchez M; Rodríguez-Vicente AE; Sanzo C; Aventín A; Puiggros A; Collado R; Heras C; Muñoz C; Delgado J; Ortega M; González MT; Marugán I; de la Fuente I; Recio I; Bosch F; Espinet B; González M; Hernández-Rivas JM; Hernández JÁ; ;
Hematol Oncol; 2016 Jun; 34(2):84-92. PubMed ID: 25689772
[TBL] [Abstract][Full Text] [Related]
36. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
37. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
Langerbeins P; Giza A; Robrecht S; Cramer P; von Tresckow J; Al-Sawaf O; Fink AM; Fürstenau M; Kutsch N; Simon F; Goede V; Hoechstetter M; Niemann CU; da Cunha-Bang C; Kater A; Dubois J; Gregor M; Staber PB; Tausch E; Schneider C; Stilgenbauer S; Eichhorst B; Fischer K; Hallek M
Blood; 2024 Jun; 143(25):2588-2598. PubMed ID: 38620092
[TBL] [Abstract][Full Text] [Related]
38. Cytogenetic Subclone Burden: A New Biomarker Predicting Chronic Lymphocytic Leukemia Patients Outcome.
Aref S; Mansour M; Abdel-Aziz S; Sabry M; Aref M; El Dosoky W
Asian Pac J Cancer Prev; 2024 Jan; 25(1):65-72. PubMed ID: 38285768
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic significance of CLL-IPI for Chinese patients with chronic lymphocytic leukemia].
Zhu HY; Wang L; Qiao J; Zou YX; Xia Y; Wu W; Cao L; Liang JH; Fan L; Xu W; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):392-397. PubMed ID: 29779348
[No Abstract] [Full Text] [Related]
40. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
